Obese Males May Have Melanoma Survival Advantage

Obese men with metastatic melanoma who are treated using targeted or immuno-therapies survive for more than twice as long as patients receiving the same treatment, but who have a normal body mass index (BMI), according to a retrospective study by researchers at the University of Texas MD Anderson Cancer Center. Their analysis of independent cohorts of metastatic melanoma patients found that the survival-boosting effects of obesity didn’t extend to female patients, nor was obesity associated with increased survival in men receiving chemotherapy.

"Obese men consistently did much better than men with a normal BMI, with nearly a doubling of overall survival," comments Jennifer McQuade, M.D., lead author of the team’s published paper in Lancet Oncology, and instructor of melanoma medical oncology at the University of Texas MD Anderson Cancer Center. However, McQuade stresses, "The public health message is not that obesity is good. Obesity is a proven risk ...